Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Jun;100(6):1603-1620.
doi: 10.1007/s00277-021-04452-9. Epub 2021 Apr 13.

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

Annika Y Classen  1   2 , Larissa Henze  3 , Marie von Lilienfeld-Toal  4 , Georg Maschmeyer  5 , Michael Sandherr  6 , Luisa Durán Graeff  1   2 , Nael Alakel  7 , Maximilian Christopeit  8 , Stefan W Krause  9 , Karin Mayer  10 , Silke Neumann  11 , Oliver A Cornely  1   2   12   13 , Olaf Penack  14 , Florian Weißinger  15 , Hans-Heinrich Wolf  16 , Jörg Janne Vehreschild  17   18   19
Affiliations
Practice Guideline

Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

Annika Y Classen et al. Ann Hematol. 2021 Jun.

Abstract

Hematologic and oncologic patients with chemo- or immunotherapy-related immunosuppression are at substantial risk for bacterial infections and Pneumocystis jirovecii pneumonia (PcP). As bacterial resistances are increasing worldwide and new research reshapes our understanding of the interactions between the human host and bacterial commensals, administration of antibacterial prophylaxis has become a matter of discussion. This guideline constitutes an update of the 2013 published guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). It gives an overview about current strategies for antibacterial prophylaxis in cancer patients while taking into account the impact of antibacterial prophylaxis on the human microbiome and resistance development. Current literature published from January 2012 to August 2020 was searched and evidence-based recommendations were developed by an expert panel. All recommendations were discussed and approved in a consensus conference of the AGIHO prior to publication. As a result, we present a comprehensive update and extension of our guideline for antibacterial and PcP prophylaxis in cancer patients.

Keywords: Bacterial infections; Neutropenia; Pneumocystis; Prophylaxis; Resistance.

PubMed Disclaimer

Conflict of interest statement

Annika Y. Classen, Larissa Henze, Luisa Durán Graeff, Karin Mayer, Silke Neumann, Stefan Krause, Hans-Heinrich Wolf, and Florian Weißinger declare that they have no conflict of interest.

Marie von Lilienfeld-Toal has received travel grants and honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, and Pfizer; is a consultant for Celgene, Gilead, Oncopeptides, MSD, 4DPharma, Janssen, and Shionogi; and received research funding from BMBF, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, DFG, Novartis, Gilead, Deutsche Krebshilfe, Celgene, and Deutsche Forschungsgemeinschaft.

Georg Maschmeyer received honoraria for lectures from Amgen, Gilead, Bristol-Myers Squibb, Merck-Serono, and Janssen-Cilag.

Michael Sandherr received honoraria for lectures from Roche and BMS.

Nael Alakel received honoraria for lectures from Basilea Pharmaceutica and honoraria for advice from Gilead, MSD Sharp & Dohme GmbH, Pfizer, and Amgen.

Maximilian Christopeit reports personal fees from Merck/MSD, GILEAD, Basilea, IQONE, and Shionogi; non-financial support and other from Robert-Koch-Institut during the conduct of the study; other from Celgene, Neovii, and Eurocept; and personal fees from JAZZ, outside the submitted work.

Olaf Penack has received honoraria and travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Pfizer, and Therakos. He has received research support from Bio Rad, Gilead, Incyte, Jazz, Neovii Biotech, Pierre Fabre, Sanofi, and Takeda. He is member of the advisory board to Jazz, Gilead, MSD, Omeros, Shionogi, and SOBI.

Oliver A. Cornely is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – CECAD, EXC 2030 – 390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Medicines Company, Melinta, Merck/MSD, Octapharma, Pfizer, and Scynexis; is a consultant to Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi; and received lecture honoraria from Al-Jazeera Pharmaceuticals, Astellas, Basilea, Gilead, Grupo Biotoscana, Merck/MSD, and Pfizer.

Janne Vehreschild has received personal fees from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM) and grants from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), (PJ-T: DLR), University of Bristol, and Rigshospitalet Copenhagen.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–2266. - PubMed
    1. Pagano L, Caira M, Rossi G, Tumbarello M, Fanci R, Garzia MG, et al. A prospective survey of febrile events in hematological malignancies. Ann Hematol. 2012;91:767–774. - PubMed
    1. Cordonnier C, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP, Alanio A, et al. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71:2379–2385. - PubMed
    1. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol - PMC - PubMed
    1. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977–987. - PubMed

Publication types

MeSH terms